87 results on '"Overeinder I"'
Search Results
2. First experience of focal pulsed field ablation for premature ventricular contractions
- Author
-
Cespon Fernandez, M, primary, Della Rocca, D G, additional, Almorad, A, additional, Vetta, G, additional, Del Monte, A, additional, Pannone, L, additional, Mouram, S, additional, Sorgente, A, additional, Sieira, J, additional, Stroker, E, additional, Bala, G, additional, Overeinder, I, additional, Chierchia, G B, additional, De Asmundis, C, additional, and Sakorzy, A, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Charge-density mapping to evaluate non-pulmonary vein substrate in patients with paroxysmal atrial fibrillation: the ACUPRED study
- Author
-
Pannone, L, primary, Mojica, J, additional, Della Rocca, D G, additional, Vergara, P, additional, Sorgente, A, additional, Overeinder, I, additional, Bala, G, additional, Almorad, A, additional, Stroker, E, additional, Sieira, J, additional, La Meir, M, additional, Brugada, P, additional, Chierchia, G B, additional, Sarkozy, A, additional, and De Asmundis, C, additional
- Published
- 2024
- Full Text
- View/download PDF
4. In-vivo mapping of human polymorphic ventricular tachycardia in Brugada syndrome
- Author
-
Pannone, L, primary, Della Rocca, D G, additional, Vergara, P, additional, Sorgente, A, additional, Overeinder, I, additional, Bala, G, additional, Almorad, A, additional, Stroker, E, additional, Pappaert, G, additional, Sieira, J, additional, La Meir, M, additional, Brugada, P, additional, Chierchia, G B, additional, Sarkozy, A, additional, and De Asmundis, C, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Age and genetics are associated with ventricular fibrillation but not with monomorphic ventricular tachycardia in Brugada syndrome
- Author
-
Pannone, L, primary, Osei, R, additional, Gauthey, A, additional, Sorgente, A, additional, Della Rocca, D G, additional, Overeinder, I, additional, Bala, G, additional, Almorad, A, additional, Stroker, E, additional, Sieira, J, additional, La Meir, M, additional, Brugada, P, additional, Chierchia, G B, additional, Van Dooren, S, additional, and De Asmundis, C, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Impact of different energy sources on the cardiac autonomic nervous system in the setting of single-shot pulmonary vein isolation
- Author
-
Del Monte, A, primary, Stroker, E, additional, Della Rocca, D, additional, Pannone, L, additional, Mouram, S, additional, Gauthey, A, additional, Overeinder, I, additional, Bala, G, additional, Sorgente, A, additional, Sieira, J, additional, Almorad, A, additional, La Meir, M, additional, Brugada, P, additional, Chierchia, G B, additional, and De Asmundis, C, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Genetic testing in children with Brugada syndrome: results from a large prospective registry
- Author
-
Pannone, L, primary, Osey, R, additional, Gauthey, A, additional, Sorgente, A, additional, Della Rocca, D G, additional, Overeinder, I, additional, Bala, G, additional, Almorad, A, additional, Stroker, E, additional, Sieira, J, additional, La Meir, M, additional, Brugada, P, additional, Chierchia, G B, additional, Van Dooren, S, additional, and De Asmundis, C, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Pulmonary vein isolation with the novel radiofrequency balloon catheter: predictors of single-shot isolation
- Author
-
Del Monte, A, primary, Almorad, A, additional, Pannone, L, additional, Della Rocca, D, additional, Mouram, S, additional, Gauthey, A, additional, Overeinder, I, additional, Bala, G, additional, Sorgente, A, additional, Stroker, E, additional, Sieira, J, additional, Brugada, P, additional, La Meir, M, additional, Chierchia, G B, additional, and De Asmundis, C, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Hybrid ablation of atrial fibrillation: long-term outcomes from a single center prospective experience
- Author
-
Mouram, S, primary, Pannone, L, additional, Della Rocca, D, additional, Gauthey, A, additional, Sorgente, A, additional, Del Monte, A, additional, Overeinder, I, additional, Bala, G, additional, Almorad, A, additional, Stroker, E, additional, Sieira, J A, additional, La Meir, M, additional, Brugada, P, additional, Chierchia, G B, additional, and De Asmundis, C, additional
- Published
- 2023
- Full Text
- View/download PDF
10. Cerebral microembolic signal burden during pulsed field ablation: preliminary results from robotically-assisted transcranial doppler and magnetic resonance imaging
- Author
-
Della Rocca, D, primary, De Asmundis, C, additional, Stroker, E, additional, Sieira, J, additional, Sorgente, A, additional, Ceccarelli, A, additional, Bala, G, additional, Del Monte, A, additional, Pannone, L, additional, Overeinder, I, additional, Ramak, R, additional, Mouram, S, additional, Almorad, A, additional, Natale, A, additional, and Chierchia, G B, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Genetics of idiopathic ventricular fibrillation
- Author
-
Pannone, L, primary, Gauthey, A, additional, Sorgente, A, additional, Monaco, C, additional, Bisignani, A, additional, Overeinder, I, additional, Bala, G, additional, Almorad, A, additional, Stroker, E, additional, Pappaert, G, additional, Sieira, J, additional, Brugada, P, additional, La Meir, M, additional, Chierchia, GB, additional, and De Asmundis, C, additional
- Published
- 2022
- Full Text
- View/download PDF
12. SCN5A mutation is associated with severity of abnormalities detected by ECG imaging in Brugada syndrome
- Author
-
Pannone, L, primary, Monaco, C, additional, Sorgente, A, additional, Gauthey, A, additional, Calburean, P-A, additional, Overeinder, I, additional, Bala, G, additional, Almorad, A, additional, Stroker, E, additional, Pappaert, G, additional, Sieira, J, additional, Brugada, P, additional, La Meir, M, additional, Chierchia, GB, additional, and De Asmundis, C, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Single procedural outcomes in the setting of percutaneous ablation for persistent atrial fibrillation: a propensity-matched score comparison between different strategies
- Author
-
Bisignani, A., Cecchini, F., Mugnai, G., Overeinder, I., Sieira, J., Osório, T.G., Miraglia, V., Monaco, C., Sofianos, D., Boveda, S., Bala, G., Ströker, E., Paparella, G., Westra, S.W., Brouwer, M.A., Brugada, P., Asmundis, C. de, Chierchia, G.B., Bisignani, A., Cecchini, F., Mugnai, G., Overeinder, I., Sieira, J., Osório, T.G., Miraglia, V., Monaco, C., Sofianos, D., Boveda, S., Bala, G., Ströker, E., Paparella, G., Westra, S.W., Brouwer, M.A., Brugada, P., Asmundis, C. de, and Chierchia, G.B.
- Abstract
Item does not contain fulltext, BACKGROUND: Catheter ablation for persistent atrial fibrillation (persAF) is associated with less favorable outcomes than for paroxysmal AF. To improve success rates, left atrial (LA) substrate modification is frequently performed in addition to pulmonary vein isolation (PVI). The purpose of the study was to compare 4 different ablation approaches using radiofrequency catheter ablation (RFCA) or cryoballoon ablation (CB-A) for persAF and to evaluate the respective outcomes on a midterm follow-up of 12 months. METHODS: We did a propensity score-matched comparison of 30 patients undergoing PVI + LA posterior wall isolation (LAPWI) with CB-A, 30 patients who underwent PVI + linear ablation (roof and mitral lines) using RFCA, 60 patients with PVI alone using CB-A, and 60 patients who had PVI alone using RFCA. The endpoint was recurrence of documented atrial tachyarrhythmias (ATas) > 30 s at 1-year follow-up. RESULTS: After 12 months, freedom from ATas after a single procedure was 83.3% in the PVI + LAPWI group, 46.7% in the PVI + linear ablation group, 58.3% in the PVI-alone CB-A group, and 61.6% PVI-alone RFCA (p = 0.03). Moreover, freedom from ATas was significantly higher comparing the PVI + LAPWI group with each of the other groups. CONCLUSIONS: In this propensity-matched comparison of strategies for persAF, LAPW ablation in addition to PVI with CB-A seems to improve 1-year outcome in comparison to PVI + linear ablation using RFCA and to PVI alone using RFCA or CB-A. Randomized comparisons are eagerly awaited.
- Published
- 2022
14. New insights into risk stratification of Brugada syndrome from high density epicardial electroanatomic mapping
- Author
-
Pannone, L, primary, Monaco, C, additional, Ramak, R, additional, Calburean, P, additional, Bisignani, A, additional, Sieira, J, additional, Kazawa, S, additional, Overeinder, I, additional, Bala, G, additional, Almorad, A, additional, Stroker, E, additional, Vergara, P, additional, Sorgente, A, additional, Chierchia, G.B, additional, and De Asmundis, C, additional
- Published
- 2021
- Full Text
- View/download PDF
15. Role of home monitoring in managing of patient with Brugada syndrome
- Author
-
Ricciardi, D., Namdar, M., Casado, Ruben, Rao, J., Rodriguez-Mañero, Moises, Overeinder, I., de Asmundis, Carlo, Wauters, K., Chierchia, Jean-Baptiste, Sarkozy, Andrea, Brugada, Pedro, Cardio-vascular diseases, and Heartrhythmmanagement
- Subjects
home monitoring ,Brugada syndrome - Abstract
No abstract available
- Published
- 2012
16. Acute coronary syndrome protocol introduction and its impact on in-hospital mortality in patients with ST-segment elevation myocardial infarction
- Author
-
Overeinder, I., Scott, Benjamin, Schoors, Danny, and Cardio-vascular diseases
- Abstract
NA
- Published
- 2012
17. Impact of transseptal puncture site on acute and mid-term outcomes during cryoballoon ablation: A comparison between anterior, medial and posterior transatrial access
- Author
-
Chierchia, G.B., Casado-Arroyo, R., Asmundis, C. de, Rodriguez-Manero, M., Sarkozy, A., Conte, G., Sieira, J., Levinstein, M., Baltogiannis, G., Giovanni, G., Overeinder, I., Ocello, S., Rosas, E., Isola, F., Brugada, P., Chierchia, G.B., Casado-Arroyo, R., Asmundis, C. de, Rodriguez-Manero, M., Sarkozy, A., Conte, G., Sieira, J., Levinstein, M., Baltogiannis, G., Giovanni, G., Overeinder, I., Ocello, S., Rosas, E., Isola, F., and Brugada, P.
- Abstract
Item does not contain fulltext, BACKGROUND: Cryoballoon ablation (CBA) (Arctic Front, Medtronic, USA) has proven very effective in achieving pulmonary vein isolation (PVI). Different transseptal (TS) puncture sites might influence CBA procedure. The aim of the present study was to analyze the influence of different TS puncture sites (anterior, medial and posterior) on the acute and midterm outcomes of CBA in a series of patients undergoing PVI for drug resistant AF. METHODS AND RESULTS: A total 103 patients (78 males, mean age: 57+/-13years) formed the study group. Transseptal punctures were performed in the anterior, medial and posterior portion of the FO in 41 (39.8%), 35 (34%) and 27 (26.2%) patients respectively. We found no statistical significant difference between the various sites of TS puncture in 1) the grade of PV occlusion (p=ns), the rate of PV isolation (p=ns), freedom from AF at a mean 12month follow-up (p=ns) and complication rates (p=ns). Mean grade of occlusion was slightly lower in the RIPV when puncturing in the posterior FO but did not reach statistical significance. Mean procedural and fluoroscopy times were significantly lower when using the inner lumen mapping catheter (ILMC) (Achieve, Medtronic, USA) than the circular mapping catheter (CMC) (Lasso, Biosense Webster, California, USA) (107.24mn vs 97.74 (p=0.001) and 25.7mn vs 19.2mn (p=0.001)). CONCLUSION: Different sites of TS puncture on the horizontal axis of the FO (anterior, medial and posterior) did not influence grades of PV occlusion, rates of isolation, mid-term outcome and rates of complications during CB ablation.
- Published
- 2013
18. Verification of pulmonary vein isolation during single transseptal cryoballoon ablation: a comparison between the classical circular mapping catheter and the inner lumen mapping catheter
- Author
-
Chierchia, G.B., Namdar, M., Sarkozy, A., Sorgente, A., de Asmundis, C., Casado-Arroyo, R., Capulzini, L., Bayrak, F., Rodriguez-Manero, M., Ricciardi, D., Rao, J.Y., Overeinder, I., Paparella, G., Brugada, P., Chierchia, G.B., Namdar, M., Sarkozy, A., Sorgente, A., de Asmundis, C., Casado-Arroyo, R., Capulzini, L., Bayrak, F., Rodriguez-Manero, M., Ricciardi, D., Rao, J.Y., Overeinder, I., Paparella, G., and Brugada, P.
- Abstract
Item does not contain fulltext, AIMS: Cryoballoon ablation has proven very effective in achieving pulmonary vein isolation (PVI). The novel Achieve inner lumen mapping catheter designed to be used in conjunction with the cryoballoon, serves as both a guidewire and a mapping catheter. To our knowledge, this is the first study comparing the latter to verification of electrical isolation with the 'traditional' circular mapping catheter. METHODS AND RESULTS: We assigned 40 consecutive patients matched for age and left atrial diameter suffering of paroxysmal atrial fibrillation to cryoballoon PVI using either the circular mapping catheter or the Achieve as a mapping catheter. Duration of procedure as well as fluoroscopy times were significantly lower in the Achieve group than in the circular mapping catheter group (111 +/- 14 min vs. 126 +/- 13 min, P < 0.005 and 22 +/- 5 min vs. 29 +/- 4 min, P < 0.0001, respectively). There were no significant differences between both groups in terms of mean degree of occlusion, mean minimal temperatures, and PVI. Pulmonary vein isolation could be documented by real-time recordings in 55% of veins in the Achieve group with mean time to isolation of 65 +/- 23 s. CONCLUSION: Cryoballoon ablation in conjunction with the novel Achieve is feasible, safe, and affords PVI in nearly all veins in similar proportions to the approach with the traditional guidewire. Furthermore, if compared to the procedure with the circular mapping catheter, cryoballoon ablation with the Achieve is significantly faster and associated to shorter fluoroscopy times.
- Published
- 2012
19. Verification of pulmonary vein isolation during single transseptal cryoballoon ablation: a comparison between the classical circular mapping catheter and the inner lumen mapping catheter
- Author
-
Chierchia, G.-B., primary, Namdar, M., additional, Sarkozy, A., additional, Sorgente, A., additional, de Asmundis, C., additional, Casado-Arroyo, R., additional, Capulzini, L., additional, Bayrak, F., additional, Rodriguez-Manero, M., additional, Ricciardi, D., additional, Rao, J. Y., additional, Overeinder, I., additional, Paparella, G., additional, and Brugada, P., additional
- Published
- 2012
- Full Text
- View/download PDF
20. Multielectrode Catheter-Based Pulsed Field Ablation of Persistent and Long-Standing Persistent Atrial Fibrillation.
- Author
-
Della Rocca DG, Sorgente A, Pannone L, Cespón-Fernández M, Vetta G, Almorad A, Bala G, Del Monte A, Ströker E, Sieira J, Doundoulakis I, Mouram S, Audiat C, Monaco C, Mohanty S, Scacciavillani R, Marcon L, Nakasone K, Zaher W, Overeinder I, Boveda S, La Meir M, Natale A, Sarkozy A, de Asmundis C, and Chierchia GB
- Abstract
Background and Aims: Rhythm control of non-paroxysmal atrial fibrillation (AF) is significantly more challenging, as a result of arrhythmia perpetuation promoting atrial substrate changes and AF maintenance. We describe a tailored ablation strategy targeting multiple left atrial (LA) sites via a pentaspline pulsed field ablation (PFA) catheter in persistent AF sustained beyond 6 months (PerAF>6m) and long-standing persistent AF (LSPAF)., Methods: The ablation protocol included the following stages: pulmonary vein antral and posterior wall isolation plus anterior roof line ablation (Stage 1); electrogram-guided substrate ablation (Stage 2); atrial tachyarrhythmia regionalization and ablation (Stage 3)., Results: Seventy-two [age:68±10years, 61.1%males; AF history: 25 (18-45) months] patients with PerAF>6m (52.8%) and LSPAF (47.2%) underwent their first PFA via the FarapulseTM system. LA substrate ablation (Stage 1 and 2) led to AF termination in 95.8% of patients. AF organized into a left-sided atrial flutter (AFlu) in 46 (74.2%) patients. The PFA catheter was used to identify LA sites showing diastolic, low-voltage electrograms and entrainment from its splines was performed to confirm the pacing site was inside the AFlu circuit. Left AFlu termination was achieved in all cases via PFA delivery. Total procedural and LA dwell times were 112±25min and 59±22 min, respectively. Major complications occurred in 2 (2.8%) patients. Single-procedure success rate was 74.6% after 14.9±2.7 months of follow-up; AF-free survival was 89.2%., Conclusions: In our cohort, PFA-based AF substrate ablation led to AF termination in 95.8% of cases. Very favorable clinical outcomes were observed during >1year of follow-up., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
21. SCN5A gene variants and arrhythmic risk in Brugada syndrome: An updated systematic review and meta-analysis.
- Author
-
Doundoulakis I, Pannone L, Chiotis S, Della Rocca DG, Sorgente A, Tsioufis P, Del Monte A, Vetta G, Piperis C, Overeinder I, Bala G, Almorad A, Ströker E, Sieira J, La Meir M, Brugada P, Tsiachris D, Sarkozy A, Chierchia GB, and de Asmundis C
- Subjects
- Humans, Electrocardiography, Genetic Predisposition to Disease, Mutation, Brugada Syndrome genetics, Brugada Syndrome physiopathology, Brugada Syndrome complications, NAV1.5 Voltage-Gated Sodium Channel genetics
- Abstract
Background: A rare gene variant in SCN5A can be found in approximately 20%-25% of patients with Brugada syndrome (BrS)., Objective: The aim of this systematic review and meta-analysis was to evaluate the differences in clinical characteristics of BrS patients with and without SCN5A rare variants and the prognostic role of SCN5A for ventricular arrhythmias in BrS., Methods: PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) were systematically searched from inception to January 2024 to identify all relevant studies. Studies were analyzed if they included patients diagnosed with BrS in whom genetic testing for SCN5A variants was performed and arrhythmic outcomes were reported., Results: A total of 17 studies with 3568 BrS patients, of whom 3030 underwent genetic testing for SCN5A variants, fulfilled the eligibility criteria and were included. Compared with SCN5A- patients, SCN5A+ BrS patients more frequently had spontaneous type 1 electrocardiogram, history of syncope, and documented arrhythmias. Furthermore, higher PQ and QRS intervals in SCN5A+ BrS patients compared with SCN5A- have been found. The pooled analysis demonstrated a significant association between the presence of SCN5A rare variants in BrS patients and the risk of major arrhythmic events, with a pooled odds ratio of 2.14 (95% confidence interval, 1.53-2.99; I
2 = 29%)., Conclusion: SCN5A+ BrS patients showed a worse clinical phenotype compared with SCN5A-. The pooled analysis demonstrated a significant association between SCN5A+ mutation status and the risk of major arrhythmic events in BrS patients., Competing Interests: Disclosures A.S. received research grants from Daiichi Sankyo and Bayer and has received speaker fees from Menarini and Bayer. M.L.M. is a consultant for AtriCure. P.B. received compensation for teaching purposes from Biotronik. G.C. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. C.dA. receives research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; and received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, LivaNova, Boston Scientific, AtriCure, and Acutus Medical Daiichi Sankyo. The remaining authors have nothing to disclose., (Copyright © 2024 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
22. Focal Pulsed Field Ablation for Premature Ventricular Contractions: A Multicenter Experience.
- Author
-
Della Rocca DG, Cespón-Fernández M, Keelani A, Raffa S, Pannone L, Almorad A, Ströker E, Borisov G, Bala G, Sieira J, Vetta G, Alothman O, Sorgente A, Audiat C, Overeinder I, Frommhold M, Del Monte A, La Meir M, Natale A, Chierchia GB, Geller JC, de Asmundis C, and Sarkozy A
- Subjects
- Humans, Male, Female, Middle Aged, Prospective Studies, Treatment Outcome, Aged, Electrophysiologic Techniques, Cardiac, Time Factors, Adult, Action Potentials, Heart Rate, Ventricular Premature Complexes physiopathology, Ventricular Premature Complexes surgery, Ventricular Premature Complexes diagnosis, Catheter Ablation methods, Feasibility Studies
- Abstract
Background: Pulsed field ablation (PFA) is a novel technology for catheter-based atrial arrhythmia treatment. Evidence of its application for ventricular arrhythmia ablation is still limited. In this study, we describe the feasibility and efficacy of focal PFA for premature ventricular contraction (PVC) ablation., Methods: A prospective cohort of 20 patients referred for PVC ablation at 2 centers was enrolled, regardless of the presence of structural heart disease, PVC morphology, or previous ablation attempts. All procedures were performed using the CENTAURI System in combination with contact force sensing catheters and 3-dimensional electroanatomical mapping systems. Energy output and the number of applications were left to the operator's discretion., Results: Eleven (55%) procedures were conducted under general anesthesia, 6 (30%) under deep sedation, and 3 (15%) under light sedation. Muscular contraction was observed in one case (5%). Median procedural and fluoroscopy times were 95.5 and 6.55 minutes, respectively. The median number of PFA applications was 8 with a median contact force of 10 g . A statistically significant (76%) reduction was observed in mean peak-to-peak bipolar electrogram voltage before and after ablation (0.707 versus 0.098 mV; P =0.008). Ventricular irritative firing was observed in 11 (55%) patients after PFA. The median follow-up was 120 days. Acute procedural success was achieved in 17 of 20 (85% [95% CI, 0.70-1]) patients. Two of the patients with procedural failure had late success with >80% clinical PVC burden suppression during follow-up, and 2 of 17 patients with acute success had late PVC recurrence, which accounts for a total of 17 of 20 (85% [95% CI, 0.70-1]) patients with chronic success. Transient ST-segment depression occurred in 1 patient, and the right bundle branch block was induced in 2 others (permanently only in one case)., Conclusions: PVC ablation using a focal PFA is feasible, effective, and safe, with promising acute and long-term results in several ventricular locations. Irritative firing is frequently observed. Coronary evaluation should be considered when targeting the outflow tract., Competing Interests: Dr La Meir is a consultant for AtriCure. Dr Chierchia received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. Dr Chierchia received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. Dr de Asmundis received research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus and compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, LivaNova, Boston Scientific, AtriCure, Acutus Medical, and Daiichi Sankyo. Dr Sorgente is a consultant for Biosense Webster and Abbott and received compensation for teaching purposes from Medtronic, Biotronik, and Microport. The other authors report no conflicts.
- Published
- 2024
- Full Text
- View/download PDF
23. Correlations of ventricular fibrillation and monomorphic ventricular tachycardia with SCN5A mutations and other clinical variables in Brugada syndrome.
- Author
-
Pannone L, Bisignani A, Osei R, Gauthey A, Sorgente A, Monaco C, Della Rocca DG, Del Monte A, Strazdas A, Mojica J, Al Housari M, Miraglia V, Mouram S, Vetta G, Paparella G, Doundoulakis I, Overeinder I, Bala G, Almorad A, Ströker E, Pappaert G, Sieira J, de Ravel T, La Meir M, Sarkozy A, Brugada P, Chierchia GB, Van Dooren S, and de Asmundis C
- Abstract
Competing Interests: Disclosures A.So. received research grants from Daiichi-Sankyo and Bayer; he has received speaker fees from Menarini and Bayer. M.L.M. is a consultant for AtriCure. A.S. is a consultant for Biosense Webster and Medtronic and received speaker fees from Biosense Webster, Biotronik, Pfizer, and MicroPort. G.C. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik. and Boston Scientific. C.d.A. receives research grants on behalf of the center from Biotronik, Medtronic, Abbott, MicroPort, Boston Scientific. and AtriCure; and received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, MicroPort, Boston Scientific, AtriCure, and Daiichi Sankyo. The remaining authors have no conflicts of interest to disclose.
- Published
- 2024
- Full Text
- View/download PDF
24. Distance-dependent neuromodulation effect during thermal ablation for atrial fibrillation.
- Author
-
Nakasone K, Tanaka K, Del Monte A, Della Rocca DG, Pannone L, Mouram S, Cespón-Fernández M, Doundoulakis I, Marcon L, Audiat C, Vetta G, Scacciavillani R, Overeinder I, Bala G, Sorgente A, Sieira J, Almorad A, Fukuzawa K, Hirata KI, Brugada P, Sarkozy A, Chierchia GB, de Asmundis C, and Ströker E
- Abstract
Introduction: Thermal atrial fibrillation (AF) ablation exerts an additive treatment effect on the cardiac autonomic nervous system (CANS). This effect is mainly reported during ablation of the right superior pulmonary vein (RSPV), modulating the right anterior ganglionated plexus (RAGP), which contains parasympathetic innervation to the sinoatrial node in the epicardial fat pad between RSPV and superior vena cava (SVC). However, a variable response to neuromodulation after ablation is observed, with little to no effect in some patients. Our objective was to assess clinical and anatomic predictors of thermal ablation-induced CANS changes, as assessed via variations in heart rate (HR) postablation., Methods: Consecutive paroxysmal AF patients undergoing first-time PV isolation by the cryoballoon (CB) or radiofrequency balloon (RFB) within a 12-month time frame and with preprocedural cardiac computed tomography (CT), were evaluated. Preablation and 24-h postablation electrocardiograms in sinus rhythm were collected and analyzed to assess HR. Anatomic evaluation by CT included the measurement of the shortest distance between the SVC and RSPV ostium (RSPV-SVC distance)., Results: A total of 97 patients (CB, n = 50 vs. RFB, n = 47) were included, with similar baseline characteristics between both groups. A significant HR increase postablation (ΔHR ≥ 15 bpm) occurred in a total of 37 patients (38.1%), without difference in number of patients between both thermal ablation technologies (CB, 19 [51%]), RFB, 18 [49%]). Independent predictors for increased HR were RSPV-SVC distance (odds ratio [OR]: 0.49, CI: 0.34-0.71, p value < .001), and age (OR: 0.94, CI: 0.89-0.98, p value = .003)., Conclusions: Thermal balloon-based PV isolation influences the CANS through its effect on the RAGP, especially in younger patients and patients with shorter RSPV-SVC distance., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
25. Advanced management of surgically corrected Ebstein's anomaly: echoguided implantation of a retrievable leadless pacemaker in the right ventricle.
- Author
-
Blankoff N, Audiat C, Della Rocca DG, Overeinder I, Almorad A, and de Asmundis C
- Published
- 2024
- Full Text
- View/download PDF
26. Predicting and Recognizing Drug-Induced Type I Brugada Pattern Using ECG-Based Deep Learning.
- Author
-
Călburean PA, Pannone L, Monaco C, Rocca DD, Sorgente A, Almorad A, Bala G, Aglietti F, Ramak R, Overeinder I, Ströker E, Pappaert G, Măru'teri M, Harpa M, La Meir M, Brugada P, Sieira J, Sarkozy A, Chierchia GB, and de Asmundis C
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Predictive Value of Tests, Retrospective Studies, Brugada Syndrome diagnosis, Brugada Syndrome physiopathology, Brugada Syndrome chemically induced, Deep Learning, Electrocardiography drug effects, Ajmaline adverse effects
- Abstract
Background: Brugada syndrome (BrS) has been associated with sudden cardiac death in otherwise healthy subjects, and drug-induced BrS accounts for 55% to 70% of all patients with BrS. This study aims to develop a deep convolutional neural network and evaluate its performance in recognizing and predicting BrS diagnosis., Methods and Results: Consecutive patients who underwent ajmaline testing for BrS following a standardized protocol were included. ECG tracings from baseline and during ajmaline were transformed using wavelet analysis and a deep convolutional neural network was separately trained to (1) recognize and (2) predict BrS type I pattern. The resultant networks are referred to as BrS-Net. A total of 1188 patients were included, of which 361 (30.3%) patients developed BrS type I pattern during ajmaline infusion. When trained and evaluated on ECG tracings during ajmaline, BrS-Net recognized a BrS type I pattern with an AUC-ROC of 0.945 (0.921-0.969) and an AUC-PR of 0.892 (0.815-0.939). When trained and evaluated on ECG tracings at baseline, BrS-Net predicted a BrS type I pattern during ajmaline with an AUC-ROC of 0.805 (0.845-0.736) and an AUC-PR of 0.605 (0.460-0.664)., Conclusions: BrS-Net, a deep convolutional neural network, can identify BrS type I pattern with high performance. BrS-Net can predict from baseline ECG the development of a BrS type I pattern after ajmaline with good performance in an unselected population.
- Published
- 2024
- Full Text
- View/download PDF
27. Empirical slow pathway ablation in patients with paroxysmal palpitations and pounding in the neck: A 15-year follow-up.
- Author
-
Doundoulakis I, Marcon L, Pannone L, Della Rocca DG, Del Monte A, Sorgente A, Bala G, Ströker E, Sieira J, Almorad A, Overeinder I, Chierchia GB, Brugada P, de Asmundis C, and Sarkozy A
- Subjects
- Humans, Follow-Up Studies, Male, Female, Middle Aged, Electrocardiography, Adult, Heart Conduction System physiopathology, Treatment Outcome, Catheter Ablation methods
- Abstract
Competing Interests: Disclosures Dr Sorgente is a consultant for Biosense Webster, Medtronic, Biotronik, and MicroPort. Dr Chierchia received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, and Boston Scientific. Dr de Asmundis received research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, and Philips; and compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, LivaNova, Boston Scientific, and Daiichi Sankyo. Dr Sarkozy is a consultant for Biosense Webster and Medtronic; and received speaker’s honoraria from Biotronik and MicroPort. All other authors have no conflicts of interest to disclose.
- Published
- 2024
- Full Text
- View/download PDF
28. Genetic Testing in Brugada Syndrome: A 30-Year Experience.
- Author
-
Pannone L, Bisignani A, Osei R, Gauthey A, Sorgente A, Monaco C, Della Rocca DG, Del Monte A, Strazdas A, Mojica J, Al Housari M, Miraglia V, Mouram S, Vetta G, Paparella G, Ramak R, Overeinder I, Bala G, Almorad A, Ströker E, Pappaert G, Sieira J, de Ravel T, La Meir M, Sarkozy A, Brugada P, Chierchia GB, Van Dooren S, and de Asmundis C
- Subjects
- Humans, Genetic Testing, Arrhythmias, Cardiac genetics, Mutation, Missense, NAV1.5 Voltage-Gated Sodium Channel genetics, Mutation, Brugada Syndrome diagnosis, Brugada Syndrome genetics
- Abstract
Background: A pathogenic/likely pathogenic variant can be found in 20% to 25% of patients with Brugada syndrome (BrS) and a pathogenic/likely pathogenic variant in SCN5A is associated with a worse prognosis. The aim of this study is to define the diagnostic yield of a large gene panel with American College of Medical Genetics and Genomics variant classification and to assess prognosis of SCN5A and non-SCN5A variants., Methods: All patients with BrS, were prospectively enrolled in the Universitair Ziekenhuis Brussel registry between 1992 and 2022. Inclusion criteria for the study were (1) BrS diagnosis; (2) genetic analysis performed with a large gene panel; (3) classification of variants following American College of Medical Genetics and Genomics guidelines. Patients with a pathogenic/likely pathogenic variant in SCN5A were defined as SCN5A
+ . Patients with a reported variant in a non-SCN5A gene or with no reported variants were defined as patients with SCN5A- . All variants were classified as missense or predicted loss of function., Results: A total of 500 BrS patients were analyzed. A total of 104 patients (20.8%) were SCN5A+ and 396 patients (79.2%) were SCN5A- . A non-SCN5A gene variant was found in 75 patients (15.0%), of whom, 58 patients (77.3%) had a missense variant and 17 patients (22.7%) had a predicted loss of function variant. At a follow-up of 84.0 months, 48 patients (9.6%) experienced a ventricular arrhythmia (VA). Patients without any variant had higher VA-free survival, compared with carriers of a predicted loss of function variant in SCN5A+ or non-SCN5A genes. There was no difference in VA-free survival between patients without any variant and missense variant carriers in SCN5A+ or non-SCN5A genes. At Cox analysis, SCN5A+ or non-SCN5A predicted loss of function variant was an independent predictor of VA., Conclusions: In a large BrS cohort, the yield for SCN5A+ is 20.8%. A predicted loss of function variant carrier is an independent predictor of VA., Competing Interests: Disclosures Dr La Meir is consultant for Atricure. Dr Brugada received compensation for teaching purposes from Biotronik. Dr Battista Chierchia received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, Acutus Medical. Dr de Asmundis receives research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; Dr de Asmundis received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Livanova, Boston Scientific, Atricure, Acutus Medical Daiichi Sankyo. The other authors report no conflicts.- Published
- 2024
- Full Text
- View/download PDF
29. Posterior wall isolation via a multi-electrode radiofrequency balloon catheter: feasibility, technical considerations, endoscopic findings and comparison with cryoballoon technologies.
- Author
-
Del Monte A, Chierchia GB, Della Rocca DG, Pannone L, Sorgente A, Bala G, Monaco C, Mouram S, Capulzini Cremonini L, Audiat C, Praet J, Ramak R, Overeinder I, Ströker E, Sieira J, La Meir M, Brugada P, Sarkozy A, de Asmundis C, and Almorad A
- Subjects
- Humans, Feasibility Studies, Treatment Outcome, Recurrence, Catheters, Cryosurgery methods, Catheter Ablation methods, Atrial Fibrillation diagnostic imaging, Atrial Fibrillation surgery, Pulmonary Veins surgery
- Abstract
Background: Posterior wall (PW) isolation is an important adjunctive ablation target in patients with non-paroxysmal atrial fibrillation (AF). Traditionally performed with point-by-point radiofrequency (RF) ablation, PW isolation has also been performed with different cryoballoon technologies. We aimed at assessing the feasibility of PW isolation with the novel RF balloon catheter Heliostar™ (Biosense Webster, CA, USA)., Methods: We prospectively enrolled 32 consecutive patients with persistent AF scheduled for first-time ablation with the Heliostar™ device. Procedural data were compared with those from 96 consecutive persistent AF patients undergoing pulmonary vein (PV) plus PW isolation with a cryoballoon device. The ratio RF balloon/cryoballoon was 1:3 for each operator involved in the study, aiming at avoiding any imbalance related to different experience., Results: Single-shot PV isolation was documented in a significantly higher number of cases with the RF balloon technology compared to cryoballoon ablation (89.8% vs. 81.0%; p = 0.02, respectively). PW isolation was achieved with a similar number of balloon applications between the two groups (11 ± 4 with the RF balloon versus 11 ± 2 with the cryoballoon; p = 0.16), but in a significantly shorter time among RF balloon patients (228 ± 72 s versus 1274 ± 277 s with cryoballoon; p < 0.001). Primary safety endpoint occurred in none of the RF balloon patients versus 5 (5.2%) patients in the cryoballoon group (p = 0.33). Primary efficacy endpoint was achieved in all (100%) RF balloon patients versus 93 (96.9%) cryoballoon ones (p = 0.57). Oesophageal endoscopy did not show any signs of thermal lesions in RF balloon patients with luminal temperature rise., Conclusions: RF balloon-based PW isolation was safe and promoted shorter procedure times compared to similar cryoballoon-based ablation procedures., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
30. Pericarditis prophylactic therapy after sinus node-sparing hybrid ablation for inappropriate sinus tachycardia/postural orthostatic sinus tachycardia.
- Author
-
de Asmundis C, Marcon L, Pannone L, Della Rocca DG, Lakkireddy D, Beaver TM, Brodt CR, Monaco C, Sorgente A, Audiat C, Vetta G, Ramak R, Overeinder I, Kronenberger R, Bala G, Almorad A, Ströker E, Sieira J, Sarkozy A, Brugada P, Chierchia GB, and La Meir M
- Abstract
Background: Pericarditis is the most common complication following hybrid sinus node-sparing ablation for inappropriate sinus tachycardia (IST)/postural orthostatic tachycardia syndrome (POTS)., Objective: The study sought to evaluate the association of prophylaxis therapy on the risk of symptomatic pericarditis following hybrid IST/POTS ablation., Methods: All consecutive patients undergoing to hybrid ablation of symptomatic IST/POTS refractory or intolerant to drugs were retrospectively analyzed. Pharmacological prophylaxis therapy was based on acetylsalicylic acid and colchicine started on the day of the ablation and continued for at least 3 months. The primary endpoint was occurrence of symptomatic pericarditis. The secondary endpoint was occurrence of pericarditis-related complications, including the following: duration of pericarditis >3 months, hospitalization for pericarditis, postpericardiectomy pleuro-pericarditis, and pericardiectomy., Results: A total of 220 patients undergone to hybrid IST/POTS ablation were included and 44 (20%) underwent prophylaxis therapy. Pericarditis occurred in 101 (45.9%) patients, with 97 (96%) in the first 5 days. At survival analysis, prophylaxis was associated with higher rate of freedom from pericarditis (81.9% vs 47.2%, log-rank P < .001). Pericarditis-related complications were low, occurring in 7 (3.2%) patients. There was no difference in pericarditis-related complications between the patients who underwent prophylaxis therapy and patients who did not. At Cox multivariate analysis, predictors of pericarditis were IST (vs POTS) (hazard ratio 0.61, 95% confidence interval0.39-0.99, P = .04) and prophylaxis therapy (hazard ratio 0.27, 95% confidence interval 0.13-0.55, P < .001)., Conclusion: In a large cohort of patients undergoing hybrid ablation for IST/POTS, a prophylaxis therapy with acetylsalicylic acid and colchicine was associated with a lower rate of symptomatic pericarditis., (© 2024 Heart Rhythm Society. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
31. Redo procedures after sinus node sparing hybrid ablation for inappropriate sinus tachycardia/postural orthostatic sinus tachycardia.
- Author
-
de Asmundis C, Marcon L, Pannone L, Della Rocca DG, Lakkireddy D, Beaver TM, Brodt CR, Monaco C, Sorgente A, Audiat C, Vetta G, Ramak R, Overeinder I, Kronenberger R, Bala G, Almorad A, Ströker E, Sieira J, Sarkozy A, Brugada P, Chierchia GB, and La Meir M
- Subjects
- Humans, Sinoatrial Node, Heart Rate, Tachycardia, Sinus diagnosis, Tachycardia, Sinus surgery, Tachycardia, Sinus drug therapy, Catheter Ablation adverse effects, Catheter Ablation methods
- Abstract
Aims: A novel sinus node (SN) sparing hybrid ablation for inappropriate sinus node tachycardia (IST)/postural orthostatic tachycardia syndrome (POTS) has been demonstrated to be an effective and safe therapeutic option in patients with symptomatic drug-resistant IST/POTS. The aim of this study was to evaluate the long-term rate of redo procedures after hybrid IST ablation and procedural strategy, outcomes and safety of redo procedures., Methods and Results: All consecutive patients from 2015 to 2023 were prospectively enrolled in the UZ Brussel monocentric IST/POTS registry. They were analysed if the following inclusion criteria were fulfilled: 1) diagnosis of IST or POTS, 2) symptomatic IST/POTS refractory or intolerant to drugs, and 3) hybrid SN sparing ablation performed. The primary endpoint was redo procedure. The primary safety endpoint was pacemaker (PM) implantation. A total of 220 patients undergone to hybrid IST ablation were included, 185 patients (84.1%) were treated for IST and 61 patients (27.7%) for POTS.After a follow-up of 73.3 ± 16.2 months, 34 patients (15.4%) underwent a redo. A total of 23 patients (67.6%) had a redo for IST recurrence and 11 patients (32.4%) for other arrhythmias. Pacemaker implantation was performed in 21 patients (9.5%). Nine patients (4.1%) had no redo procedure and experienced sick sinus syndrome requiring a PM. Twelve patients (5.4%) received a PM as a shared therapeutic choice combined with SN ablation procedure., Conclusion: In a large cohort of patients the long-term free survival from redo procedure after hybrid IST ablation was 84.6% with a low PM implantation rate., Competing Interests: Conflict of interest: C.d.A receives research grants on behalf of the centre from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; C.d.A. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Livanova, Boston Scientific, AtriCure, and Acutus Medical Daiichi Sankyo. A.S. received research grants from Daiichi Sankyo and Bayer; he has received speaker fees from Menarini and Bayer. PB received compensation for teaching purposes from Biotronik. G.C. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. MLM is consultant for AtriCure. The remaining authors have nothing to disclose., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
32. Coronary artery disease in atrial fibrillation ablation: impact on arrhythmic outcomes.
- Author
-
Cappello IA, Pannone L, Della Rocca DG, Sorgente A, Del Monte A, Mouram S, Vetta G, Kronenberger R, Ramak R, Overeinder I, Bala G, Almorad A, Ströker E, Sieira J, La Meir M, Belsack D, Sarkozy A, Brugada P, Tanaka K, Chierchia GB, Gharaviri A, and de Asmundis C
- Subjects
- Humans, Treatment Outcome, Heart Atria, Recurrence, Atrial Fibrillation diagnosis, Atrial Fibrillation epidemiology, Atrial Fibrillation surgery, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease epidemiology, Coronary Artery Disease surgery, Catheter Ablation adverse effects, Catheter Ablation methods, Pulmonary Veins diagnostic imaging, Pulmonary Veins surgery
- Abstract
Aims: Catheter ablation (CA) is an established treatment for atrial fibrillation (AF). A computed tomography (CT) may be performed before ablation to evaluate the anatomy of pulmonary veins. The aim of this study is to investigate the prevalence of patients with coronary artery disease (CAD) detected by cardiac CT scan pre-ablation and to evaluate the impact of CAD and revascularization on outcomes after AF ablation., Methods and Results: All consecutive patients with AF diagnosis, hospitalized at Universitair Ziekenhuis Brussel, Belgium, between 2015 and 2019, were prospectively screened for enrolment in the study. Inclusion criteria were (i) AF diagnosis, (ii) first procedure of AF ablation with cryoballoon CA, and (iii) contrast CT scan performed pre-ablation. A total of 576 consecutive patients were prospectively included and analysed in this study. At CT scan, 122 patients (21.2%) were diagnosed with CAD, of whom 41 patients (7.1%) with critical CAD. At survival analysis, critical CAD at CT scan was a predictor of atrial tachyarrhythmia (AT) recurrence during the follow-up, only in Cox univariate analysis [hazard ratio (HR) = 1.79] but was not an independent predictor in Cox multivariate analysis. At Cox multivariate analysis, independent predictors of AT recurrence were as follows: persistent AF (HR = 2.93) and left atrium volume index (HR = 1.04)., Conclusion: In patients undergoing CT scan before AF ablation, critical CAD was diagnosed in 7.1% of patients. Coronary artery disease and revascularization were not independent predictors of recurrence; thus, in this patient population, AF ablation should not be denied and can be performed together with CAD treatment., Competing Interests: Conflict of interest: Ant.S. received research grants from Daiichi-Sankyo and Bayer; he has received speaker fees from Menarini and Bayer. M.L.M. is consultant for AtriCure. P.B. received compensation for teaching purposes from Biotronik. G.B.C. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. C.d.A. receives research grants on behalf of the centre from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; C.d.A. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, LivaNova, Boston Scientific, AtriCure, Acutus Medical, and Daiichi-Sankyo. The remaining authors have nothing to disclose., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
33. Impact of anesthetic management on catheter ablation for premature ventricular complexes: insights during the COVID-19 outbreak.
- Author
-
Kazawa S, Sieira J, Bala G, Miraglia V, Al Housari M, Strazdas A, Monaco C, Pannone L, Bisignani A, Overeinder I, Almorad A, Raes M, Weyns M, Ghijselings I, Beckers S, Brugada P, Chierchia GB, de Asmundis C, and Ströker E
- Subjects
- Humans, Anesthesia, Local, Treatment Outcome, COVID-19, Ventricular Premature Complexes surgery, Catheter Ablation methods, Anesthetics
- Abstract
Background: The influence of divergent anesthesia types during ablation of premature ventricular complexes (PVCs) is not known. While previously performed under general anesthesia (GA) at our institution, these procedures were exclusively performed under local anesthesia (LA) ± minimal sedation during the COVID-19 outbreak for logistic reasons., Methods: One hundred and eight consecutive patients (82 GA versus 26 LA) undergoing PVC ablation at our center were evaluated. Intraprocedural PVC burden (over 3 min) pre-ablation was measured twice: (1) at the start (before GA induction) and (2) before catheter insertion (after GA induction). Upon cessation of ablation and after a waiting period of ≥ 15 min, acute ablation success (AAS) was defined as absence of PVCs until the end of the recording period., Results: Intraprocedural PVC burden was not significantly different between LA versus GA group: (1) 17.8 ± 3% vs 12.7 ± 2%, P = 0.17 and (2) 10.0 ± 3% vs 7.4 ± 1%, P = 0.43, respectively. Activation mapping-based ablation was performed significantly more in the LA vs GA group (77% vs 26% of patients, P < 0.001, respectively). AAS was significantly higher in LA vs GA group: 22/26 (85%) vs 41/82 (50%), respectively, P < 0.01. After multivariable analysis, LA was the only independent predictor for AAS (OR 13, 95% CI 1.57-107.4, P = 0.017)., Conclusion: Ablation of PVC under LA presented significantly higher AAS rate compared to GA. The procedure under GA might be complicated by PVC inhibition (after catheter insertion/during mapping) and PVC disinhibition post-extubation., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
34. Pulmonary Vein Remodeling Between Atrial Fibrillation Subtypes: A Matched Comparison Cardiac Computed Tomography-Based Study Between Patients With Paroxysmal and Persistent Atrial Fibrillation.
- Author
-
Housari MA, Miraglia V, Terasawa M, Kazawa S, Monte AD, Bala G, Pannone L, Della Rocca DG, Cosyns B, Droogmans S, Tanaka K, Belsack D, De Mey J, Overeinder I, Almorad A, Sieira J, Brugada P, Sarkozy A, Chierchia GB, de Asmundis C, and Ströker E
- Subjects
- Humans, Radiography, Heart Atria diagnostic imaging, Tomography, Treatment Outcome, Atrial Fibrillation diagnostic imaging, Atrial Fibrillation surgery, Pulmonary Veins diagnostic imaging, Pulmonary Veins surgery, Catheter Ablation methods
- Abstract
Although pulmonary vein (PV) isolation (PVI) is the cornerstone for atrial fibrillation (AF) ablation, no data exist comparing PV anatomy between AF subtypes directly. We aimed to compare PV anatomic characteristics between paroxysmal (PAF) and persistent AF (PeAF) in a matched population using cardiac computed tomography (CCT). Fifty-eight PeAF patients (with CCT prior first AF ablation procedure, absence of valvular disease/previous cardiac intervention), and 58 age-, sex-, body surface area-matched PAF patients were evaluated for left atrial (LA) and PV anatomy: ostial area, ovality index (OVI), transverse/frontal angles. In PeAF vs PAF group, beside higher LA volume index (LAVI), PVs' ostial areas were significantly larger (between 64 - 101 mm
2 , P < 0.001 for all PVs; remaining valid after LAVI adjustment for left superior [LS], left inferior [LI], and right inferior [RI]PV); left PVs were less oval (0.7 - 0.11 OVI decrease, P =0.039 for LSPV; P = 0.012 for LIPV); LSPV (P = 0.019), LIPV (P < 0.001), RIPV (P = 0.029) were more posteriorly directed; whereas LSPV (P = 0.002), and right superior PV (P = 0.043) were more superiorly directed. Incidence of anatomic variations or early branching was not different. This study showed significant anatomical PV differences between patients with PeAF and PAF, in terms of PV orientation, ostial size and ovality. Anticipating such anatomical differences may aid in choosing the adequate catheter design and technology for PeAF ablation., Competing Interests: Declaration of Competing Interest Dr. de Asmundis reports speaker fees for Medtronic, Biotronik, Biosense Webster, Abbott, and Boston Scientific; teaching honoraria from Medtronic, Biotronik, Abbott, and Boston Scientific; proctoring honoraria from Medtronic, Abbott, and Biotronik. Dr. Chierchia reports speaker fees for Medtronic, Biotronik, Biosense Webster, and Abbott; teaching honoraria from Medtronic and Biotronik; proctoring honoraria from Medtronic. Dr. Brugada reports consulting fees and speaker honoraria from Medtronic. Dr. Miraglia has received an educational grant from the “Foundation Enrico and Enrica Sovena.” The remaining authors have no competing interests to declare., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
35. Atrial Abnormalities in Brugada Syndrome: Evaluation With ECG Imaging.
- Author
-
Bisignani A, Pannone L, Del Monte A, Eltsov I, Cappello IA, Sieira J, Monaco C, Bala G, Mouram S, Della Rocca DG, Ströker E, Overeinder I, Almorad A, Pappaert G, Gauthey A, de Ravel T, Van Dooren S, Sorgente A, La Meir M, Sarkozy A, Brugada P, Chierchia GB, and de Asmundis C
- Subjects
- Humans, Electrocardiography methods, Ajmaline, Brugada Syndrome diagnostic imaging, Brugada Syndrome genetics, Atrial Fibrillation complications, Atrial Fibrillation diagnostic imaging, Cardiomyopathies
- Abstract
Background: Patients with Brugada syndrome (BrS) have an increased risk of arrhythmias, including atrial tachyarrhythmias (ATas)., Objectives: The purpose of this study was to assess underlying atrial cardiomyopathy in BrS and the effect of ajmaline (AJM) test on the atrium of BrS patients using electrocardiogram imaging (ECGI)., Methods: All consecutive patients diagnosed with BrS in a monocentric registry were screened and included if they met the following criteria: 1) BrS diagnosed following current recommendations; and 2) ECGI map performed before and after AJM with a standard protocol. Consecutive patients with no structural heart disease or BrS who had undergone ECGI were included as a control group. Genetic analysis for SCN5A was performed in all BrS patients. Total atrial conduction time (TACT) and local atrial conduction time (LACT) were calculated from atrial ECGI. The primary endpoint was ATas during follow-up., Results: Forty-three consecutive BrS patients and 40 control patients were included. Both TACT and LACT were significantly prolonged in BrS patients compared with control patients. Furthermore, TACT and LACT were significantly higher after AJM administration and in BrS patients who were carriers of a pathogenic/likely pathogenic SCN5A variant. After a mean follow-up of 40.9 months, 6 patients experienced a first ATa occurrence (all in the BrS group, 13.9%). TACT was the only independent predictor of ATas with a cutoff of >138.5 ms (sensitivity 0.92 [95% CI: 0.83-0.98], specificity 0.70 [95% CI: 0.59-0.81])., Conclusions: ECGI-calculated TACT and LACT are significantly prolonged in BrS patients compared with control patients, and in BrS patients after AJM. This may be consistent with a concealed atrial cardiomyopathy in BrS., Competing Interests: Funding Support and Author Disclosures Dr La Meir is a consultant for Atricure. Dr Brugada has received compensation for teaching purposes from Biotronik. Dr Chierchia has received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. Dr de Asmundis receives research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; and has received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Livanova, Boston Scientific, Atricure, Acutus Medical, and Daiichi Sankyo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
36. Safety of the Radiofrequency Balloon for Pulmonary Vein Isolation: A Focus on Lesion Metric Analysis of Posterior Electrodes.
- Author
-
Almorad A, Del Monte A, Teumer Y, El Haddad M, Pannone L, Della Rocca DG, Audiat C, Cespón-Fernández M, Mouram S, Ramak R, Overeinder I, Bala G, Sorgente A, Ströker E, Sieira J, Brugada P, La Meir M, de Asmundis C, and Chierchia GB
- Abstract
Previous clinical studies on pulmonary vein isolation (PVI) with radiofrequency balloons (RFB) reported safe and effective procedures for a 20 s RF delivery via posterior electrodes. Recent recommendations from the manufacturer suggest reducing the application time to 15 s on the posterior wall (PW) when facing the esophagus region. Here, we retrospectively assess whether 15 s of RF delivery time on posterior electrodes is safe while still ensuring lesion metrics of sufficient quality. This retrospective study included 133 patients with paroxysmal and persistent atrial fibrillation who underwent PVI using an RFB (Heliostar, Biosense Webster, Inc., Irvine, CA, USA) at two European centers. The ablation protocol was set for an RF duration of 20 s/60 s for the posterior/anterior electrodes. A multielectrode temperature probe was systematically used. In the case of an esophageal temperature rise (ETR) above 42 °C (ETR+), an endoscopic evaluation was performed. All posterior electrode lesion metric dynamics (temperature (T) and impedance (Z)) were collected from the RFB generator and analyzed offline. In total, 2435 posterior electrode applications were analyzed. With an RF delivery of 19.8 (19.7-19.8) s, the median impedance drop was 18.4 (12.2-25.2) Ω, while the temperature rise was 11.1 (7.1-14.9) °C. Accordingly, impedance (84.6 (79.3-90.2) Ω) and temperature plateaus (38 (35.3-41.1) °C) were reached at 13.9 (10.6-16) s and 16.4 (12.6-18.5) s, respectively. Overall, 99.6% and 95.8% of electrodes reached 90% (16.6 Ω) and 95% (17.5 Ω) of their impedance drops within 15 s of RF delivery, while 97.2% and 92.8% achieved 90% (34.2 °C) and 95% (36.1 °C) of their temperature rise to reach the plateaus within 15 s of RF delivery. An ETR >42 °C occurred in 37 (30.1%) patients after 17.7 ± 2.3 s of RF delivery. In the ETR+ group, the impedance drop and temperature rise on the posterior electrodes were higher compared to patients where ETR was <42 °C. Two asymptomatic thermal esophageal injuries were observed. In conclusion, 15 s of RF delivery on the posterior electrodes provides a good balance between safety, with no esophageal temperature rise, and efficacy with high-profile lesion metrics.
- Published
- 2023
- Full Text
- View/download PDF
37. 3D mapping challenges in hybrid video-assisted thoracoscopic surgical ablation of Brugada syndrome.
- Author
-
Eltsov I, Pannone L, Ramak R, Monaco C, Della Rocca DG, Bala G, Kronenberger R, Overeinder I, Almorad A, Stroker E, Sieira J, Brugada P, Sarkozy A, Chierchia GB, de Asmundis C, and La Meir M
- Abstract
Objectives: Brugada syndrome is a life-threatening disease with an arrhythmogenic substrate located in the epicardium of right ventricle outflow tract. Therefore, the correct region identification is crucial for a successful ablation procedure. Various mapping techniques can be adopted to elaborate this issue, but they were all initially developed for endovascular use., Methods: In this study, we analysed 21 consecutive hybrid video-assisted thoracoscopic ablation of Brugada syndrome, performed using different mapping systems to identify the ablation target and confirm the elimination of arrhythmogenic substrate; 35 maps have been analysed., Results: Acute success of epicardial right ventricle outflow tract ablation has been achieved in 100% of procedures, no periprocedural complications have been observed; HD Grid catheter showed higher area identification speed and faster fractionated potentials visualization; Rhythmia system has demonstrated the best map density; Carto 3 system showed a significant advantage in patient preparation time, but mapping speed was reduced due to focal catheter use only., Conclusions: All tested electro anatomical mapping systems can be used for hybrid video-assisted thoracoscopic ablation with same clinical success; however, accuracy and efficacy of mapping systems are heterogenous and highly dependent on proper patient preparation, mapping system and physician skills., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.)
- Published
- 2023
- Full Text
- View/download PDF
38. Outcomes of pulmonary vein isolation with radiofrequency balloon vs. cryoballoon ablation: a multi-centric study.
- Author
-
Almorad A, Del Monte A, Della Rocca DG, Pannone L, Ramak R, Overeinder I, Bala G, Ströker E, Sieira J, Dubois A, Sorgente A, El Haddad M, Iacopino S, Boveda S, de Asmundis C, and Chierchia GB
- Subjects
- Humans, Prospective Studies, Pulmonary Veins, Atrial Fibrillation, Atrial Appendage, Esophageal Fistula
- Abstract
Aims: Cryoballoon (CB) ablation is the mainstay of single-shot pulmonary vein isolation (PVI). A radiofrequency balloon (RFB) catheter has recently emerged as an alternative. However, these two technologies have not been compared. This study aims to evaluate the freedom from atrial tachyarrhythmias (ATas) at 1 year: procedural characteristics, efficacy, and safety of the novel RFB compared with CB for PVI in patients with paroxysmal atrial fibrillation (AF)., Methods and Results: This prospective multi-centre study included consecutive patients with symptomatic drug-resistant paroxysmal AF who underwent PVI with RFB or CB between July 2021 and January 2022 from three European centres. A total of 375 consecutive patients were included, 125 in the RFB group and 250 in the CB. Both groups had comparable clinical characteristics. At 12.33 ± 4.91 months, ATas-free rates were 83.20% and 82.00% in the RFB and CB groups, respectively (P > 0.05). Compared with the CB group, the RFB group showed a shorter procedure time [59.91 (45.80-77.12) vs. 77.0 (35.13-122.71) min (P < 0.001)], dwell time [19.59 (14.41-30.24) vs. 27.03 (17.11-57.21) min (P = 0.04)], time to isolation, and thermal energy delivery in all pulmonary veins (P < 0.001). First-pass isolation was comparable. No major complications occurred in either group, with no stroke, atrio-oesophageal fistula, or permanent phrenic nerve injury. Transient phrenic nerve palsy occurred more frequently with CB than RFB (7.20% vs. 3.20%; P = 0.02). Oesophageal temperature rise occurred in 21 (16.8%) patients in the RFB group, and gastroscopy showed erythema in two of them with complete recovery after 30 days., Conclusions: The RFB appears to have a safety and efficacy profile similar to that of the CB for PVI. Shorter procedural times appear to be driven by shorter left atrial dwell and thermal delivery times., Competing Interests: Conflict of interest: A.A. received research grants and compensation for teaching purposes from Abbott, Biosense-Webster, Medtronic, and Microport. A.S. received research grants from Daiichi-Sankyo and Bayer; he has received speaker fees from Menarini and Bayer. M.E.H. is a consultant for Biosense-Webster Inc. not related to this work. S.B. is a consultant for Medtronic, Boston Scientific, Microport, and Zoll. G.-B.C. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. C.d.A. received research grants from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; C.d.A. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Livanova, Boston Scientific, Atricure, Acutus Medical, and Daiichi Sankyo. All remaining authors have declared no conflicts of interest., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
39. Genetics in Probands With Idiopathic Ventricular Fibrillation: A Multicenter Study.
- Author
-
Pannone L, Gauthey A, Conte G, Osei R, Campanale D, Baldi E, Berne P, Vicentini A, Vergara P, Sorgente A, Rootwelt-Norberg C, Della Rocca DG, Monaco C, Bisignani A, Miraglia V, Spolverini M, Paparella G, Overeinder I, Bala G, Almorad A, Ströker E, de Ravel T, Medeiros-Domingo A, Sieira J, Haugaa KH, Brugada P, La Meir M, Auricchio A, Chierchia GB, Van Dooren S, and de Asmundis C
- Subjects
- Humans, Retrospective Studies, Arrhythmias, Cardiac complications, Genetic Testing, Ventricular Fibrillation
- Abstract
Background: Different genes have been associated with idiopathic ventricular fibrillation (IVF); however, there are no studies correlating genotype with phenotype., Objectives: The aim of this study was to define the genetic background of probands with IVF using large gene panel analysis and to correlate genetics with long-term clinical outcomes., Methods: All consecutive probands with a diagnosis of IVF were included in a multicenter retrospective study. All patients had: 1) IVF diagnosis throughout the follow-up; and 2) genetic analysis with a broad gene panel. All genetic variants were classified as pathogenic/likely pathogenic (P+), variants of unknown significance (VUS) or no variants (NO-V), following current guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. The primary endpoint was occurrence of ventricular arrhythmias (VA)., Results: Forty-five consecutive patients were included. A variant was found in 12 patients, 3 P+ and 9 VUS carriers. After a mean follow-up time of 105.0 months, there were no deaths and 16 patients (35.6%) experienced a VA. NO-V patients had higher VA free survival during the follow-up, compared with both VUS (72.7% vs 55.6%, log-rank P < 0.001) and P+ (72.7% vs 0%, log-rank P = 0.013). At Cox analysis, P+ or VUS carrier status was a predictor of VA occurrence., Conclusions: In probands with IVF, undergoing genetic analysis with a broad panel, the diagnostic yield for P+ is 6.7%. P+ or VUS carrier status is a predictor of VA occurrence., Competing Interests: Funding Support and Author Disclosures This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Dr Osei is supported by the Bridge 2017: IGenCare: Integrated Personalised Medical Genomics Care Solution for Patients With Rare Genetic Diseases grant of Innoviris, Brussels. Dr Berne has received compensation for teaching purposes from Biotronik. Dr Bisignani is a consultant for Biotronik. Dr Miraglia has received an educational grant from the Enrico and Enrica Sovena Foundation. Dr Medeiros-Domingo is the founder and medical director of SwissDNAlysis. Dr La Meir is a consultant for Atricure. Dr Auricchio is a consultant for Abbott, Boston Scientific, Backbeat, Cairdac, Corvia, Medtronic, Microport CRM, Philips, XSpline; participates in clinical trials sponsored by Bayer AG, Boston Scientific, Medtronic, and Microport CRM. Dr Chierchia has received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. Dr de Asmundis has received research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; has received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Livanova, Boston Scientific, Atricure, Acutus Medical, Daiichi Sankyo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
40. A failed catheter ablation of atrial fibrillation is associated with more advanced remodeling and reduced efficacy of further thoracoscopic ablation.
- Author
-
Wesselink R, Vroomen M, Overeinder I, Neefs J, van den Berg NWE, Meulendijks ER, Piersma FR, Al-Shama RFM, de Vries TAC, Verstraelen TE, Luermans J, Maesen B, de Asmundis C, Chierchia GB, La Meir M, Pison L, van Boven WJP, Driessen AHG, and de Groot JR
- Subjects
- Humans, Treatment Outcome, Heart Atria, Fibrosis, Recurrence, Atrial Fibrillation complications, Atrial Fibrillation surgery, Catheter Ablation adverse effects
- Abstract
Introduction and Objectives: Recent observations suggest that patients with a previous failed catheter ablation have an increased risk of atrial fibrillation (AF) recurrence after subsequent thoracoscopic AF ablation. We assessed the risk of AF recurrence in patients with a previous failed catheter ablation undergoing thoracoscopic ablation., Methods: We included patients from 3 medical centers. To correct for potential heterogeneity, we performed propensity matching to compare AF freedom (freedom from any atrial tachyarrhythmia> 30 s during 1-year follow-up). Left atrial appendage tissue was analyzed for collagen distribution., Results: A total of 705 patients were included, and 183 had a previous failed catheter ablation. These patients had fewer risk factors for AF recurrence than ablation naïve controls: smaller indexed left atrial volume (40.9± 12.5 vs 43.0±12.5 mL/m
2 , P=.048), less congestive heart failure (1.5% vs 8.9%, P=.001), and less persistent AF (52.2% vs 60.3%, P=.067). However, AF history duration was longer in patients with a previous failed catheter ablation (6.5 [4-10.5] vs 4 [2-8] years; P<.001). In propensity matched analysis, patients with a failed catheter ablation were at a 68% higher AF recurrence risk (OR, 1.68; 95%CI, 1.20-2.15; P=.034). AF freedom was 61.1% in patients with a previous failed catheter ablation vs 72.5% in ablation naïve matched controls. On histology of the left atrial appendage (n=198), patients with a failed catheter ablation had a higher density of collagen fibers., Conclusions: Patients with a prior failed catheter ablation had fewer risk factors for AF recurrence but more frequently had AF recurrence after thoracoscopic AF ablation than ablation naïve patients. This may in part be explained by more progressed, subclinical, atrial fibrosis formation., (Copyright © 2022 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
41. Hybrid atrial fibrillation ablation: long-term outcomes from a single-centre 10-year experience.
- Author
-
Pannone L, Mouram S, Della Rocca DG, Sorgente A, Monaco C, Del Monte A, Gauthey A, Bisignani A, Kronenberger R, Paparella G, Ramak R, Overeinder I, Bala G, Almorad A, Ströker E, Sieira J, Brugada P, Chierchia GB, La Meir M, and de Asmundis C
- Subjects
- Humans, Follow-Up Studies, Heart Atria, Retrospective Studies, Tachycardia, Treatment Outcome, Atrial Fibrillation diagnosis, Atrial Fibrillation surgery, Ablation Techniques
- Abstract
Aims: Hybrid atrial fibrillation (AF) ablation is a promising approach in non-paroxysmal AF. The aim of this study is to assess the long-term outcomes of hybrid ablation in a large cohort of patients after both an initial and as a redo procedure., Methods and Results: All consecutive patients undergoing hybrid AF ablation at UZ Brussel from 2010 to 2020 were retrospectively evaluated. Hybrid AF ablation was performed in a one-step procedure: (i) thoracoscopic ablation followed by (ii) endocardial mapping and eventual ablation. All patients received PVI and posterior wall isolation. Additional lesions were performed based on clinical indication and physician judgement. Primary endpoint was freedom from atrial tachyarrhythmias (ATas). A total of 120 consecutive patients were included, 85 patients (70.8%) underwent hybrid AF ablation as first procedure (non-paroxysmal AF 100%), 20 patients (16.7%) as second procedure (non-paroxysmal AF 30%), and 15 patients (12.5%) as third procedure (non-paroxysmal AF 33.3%). After a mean follow-up of 62.3 months ± 20.3, a total of 63 patients (52.5%) experienced ATas recurrence. Complications occurred in 12.5% of patients. There was no difference in ATas between patients undergoing hybrid as first vs. redo procedure (P = 0.53). Left atrial volume index and recurrence during blanking period were independent predictors of ATas recurrence., Conclusion: In a large cohort of patients undergoing hybrid AF ablation, the survival from ATas recurrence was 47.5% at ≈5 years follow-up. There was no difference in clinical outcomes between patients undergoing hybrid AF ablation as first procedure or as a redo., Competing Interests: Conflict of interest: A.S. received research grants from Daiichi-Sankyo and Bayer; he has received speaker fees from Menarini and Bayer. P.B. received compensation for teaching purposes from Biotronik. G.B.C. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, Acutus Medical. M.L.M. is consultant for Atricure. C.d.A. receives research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; C.d.A. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Livanova, Boston Scientific, Atricure, Acutus Medical Daiichi Sankyo. The remaining authors have nothing to disclose., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
42. Pulmonary vein isolation with the radiofrequency balloon catheter: a single centre prospective study.
- Author
-
Del Monte A, Almorad A, Pannone L, Della Rocca DG, Bisignani A, Monaco C, Mouram S, Ramak R, Gauthey A, Overeinder I, Bala G, Sorgente A, Ströker E, Sieira J, Brugada P, La Meir M, Chierchia GB, and de Asmundis C
- Subjects
- Male, Humans, Middle Aged, Aged, Female, Treatment Outcome, Follow-Up Studies, Prospective Studies, Tachycardia surgery, Catheters, Recurrence, Pulmonary Veins surgery, Atrial Fibrillation diagnosis, Atrial Fibrillation surgery, Catheter Ablation adverse effects, Catheter Ablation methods
- Abstract
Aims: The multielectrode radiofrequency balloon catheter (RFB) has been developed to achieve safe and effective pulmonary vein isolation (PVI) for atrial fibrillation (AF) ablation. This single-centre study aimed to evaluate the midterm clinical outcome and predictors of single-shot PVI with the novel RFB., Methods and Results: All consecutive patients with symptomatic paroxysmal or persistent AF undergoing first-time PVI with the RFB were prospectively included. Clinical and procedural parameters were systematically collected. The primary safety endpoint was defined as any major periprocedural complications. The primary efficacy endpoint consisted of freedom from any atrial tachyarrhythmias (ATas) lasting >30 s during the follow-up after a 3-month blanking period. Persistent single-shot PVI was defined as PVI achieved with a single RFB application without acute reconnection. A total of 104 consecutive patients (mean age 64.3 ± 11.4 years, 56.7% males) were included. 15 patients (14.4%) presented with persistent AF. The procedure time was 59.0 min with a dwell time of 20.0 min. One major complication occurred in one patient. At a mean follow-up of 10.1 ± 5.3 months, freedom from ATas was 82.9%. ATas occurred in 14 patients, 11/69 patients (15.9%) with paroxysmal AF and 3/13 (23.1%) with persistent AF. The best cut-offs to predict persistent single-shot PVI were impedance drop >19.2 Ω [area under the receiver operator characteristic curve (AUC) 0.74] and temperature rise >11.1° C (AUC 0.77)., Conclusion: In a large cohort of patients undergoing PVI with the RFB, the complication rate was 1%. At a mid-term follow-up of 10.1 ± 5.3 months, freedom from ATas was 82.9%. Specific cut-offs of impedance drop and temperature rise may be useful to predict persistent single-shot isolation., Competing Interests: Conflict of interest: A.B. is a consultant for Biotronik. A.S. received research grants from Daiichi Sankyo and Bayer; he has received speaker fees from Menarini and Bayer. P.B. received compensation for teaching purposes from Biotronik. M.L.M. is a consultant for Atricure. G.-B.C. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, Acutus Medical. C.d.A. receives research grants on behalf of the centre from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; C.d.A. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Livanova, Boston Scientific, Atricure, Acutus Medical, Daiichi Sankyo. All remaining authors have declared no conflicts of interest., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
43. Heart rate variability and microvolt T wave alternans changes during ajmaline test may predict prognosis in Brugada syndrome.
- Author
-
Călburean PA, Pannone L, Sorgente A, Gauthey A, Monaco C, Strazdas A, Almorad A, Bisignani A, Bala G, Ramak R, Overeinder I, Ströker E, Pappaert G, Van Dooren S, de Ravel T, La Meir M, Brugada P, Sieira J, Chierchia GB, and de Asmundis C
- Subjects
- Humans, Heart Rate, Isoproterenol, Arrhythmias, Cardiac, Electrocardiography, Prognosis, Ajmaline pharmacology, Brugada Syndrome diagnosis
- Abstract
Purpose: Drug-induced type I Brugada syndrome (BrS) is associated with a ventricular arrhythmia (VA) rate of 1 case per 100 person-years. This study aims to evaluate changes in electrocardiographic (ECG) parameters such as microvolt T wave alternans (mTWA) and heart rate variability (HRV) at baseline and during ajmaline testing for BrS diagnosis., Methods: Consecutive patients diagnosed with BrS during ajmaline testing with 5-year follow-up were included in this study. For comparison, a negative ajmaline control group and an isoproterenol control group were also included. ECG recordings during ajmaline or isoproterenol test were divided in two timeframes from which ECG parameters were calculated: a 5-min baseline timeframe and a 5-min drug timeframe., Results: A total of 308 patients with BrS were included, 22 (0.7%) of which suffered VAs during follow-up. One hundred patients were included in both isoproterenol and negative ajmaline control groups. At baseline, there was no difference in ECG parameters between control groups and patients with BrS, nor between BrS with and without VAs. During ajmaline testing, BrS with VAs presented longer QRS duration [159 ± 34 ms versus 138 (122-155) ms, p = 0.006], higher maximum mTWA [33.8 (14.0-114) µV versus 8.00 (3.67-28.2) µV, p = 0.001], and lower power in low frequency band [25.6 (5.8-53.8) ms
2 versus 129.5 (52.7-286) ms2 , p < 0.0001] when compared to BrS without VAs., Conclusions: Ajmaline induced important HRV changes similar to those observed during isoproterenol. Increased mTWA was observed only in patients with BrS. BrS with VAs during follow-up presented worse changes during ajmaline test, including lower LF power and higher maximum mTWA which were independent predictors of events., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)- Published
- 2023
- Full Text
- View/download PDF
44. Pulmonary vein size is associated with reconnection following cryoballoon ablation of atrial fibrillation.
- Author
-
Mugnai G, Cecchini F, Stroker E, Paparella G, Iacopino S, Sieira J, De Greef Y, Tomasi L, Bolzan B, Bala G, Overeinder I, Almorad A, Gauthey A, Sorgente A, Ribichini FL, de Asmundis C, and Chierchia GB
- Subjects
- Humans, Middle Aged, Aged, Pulmonary Veins surgery, Atrial Fibrillation diagnostic imaging, Atrial Fibrillation surgery
- Abstract
Background: The second-generation cryoballoon (CB) has proven to be a highly effective ablative strategy in patients with symptomatic atrial fibrillation (AF). This study sought to investigate the anatomical characteristics of pulmonary veins (PVs) and the relationship between their size, ovality, and late reconnections in a large cohort of patients undergoing repeat ablation for recurrence of atrial arrhythmias., Methods and Results: A total of 152 consecutive patients (98 males, 64.5%; mean age 64.9 ± 9.6 years) underwent a repeat ablation for recurrent atrial tachyarrhythmias after a median time of 6.5 months [IQR 11] from the index CB ablation. All repeat ablations were performed using a 3-dimensional electro-anatomical mapping system. Among all 593 PVs, 134 (22.6%) showed a late PV reconnection in 95 patients (0.88 per patient), at the time of repeat ablation procedure. There was a significant difference in ovality between left- and right-sided PVs (p < 0.001). Greater diameters of left superior PV, left inferior PV, and right inferior PV ostia (both maximum and minimum) and higher index ovality were significantly associated with late PV reconnection., Conclusions: The rate of late PV reconnection after CB ablation was low (0.88 PVs/patient). Left-sided PVs were more oval than septal PVs. Larger PV dimensions and higher ovality index were significantly associated with reconnections in all PVs except for RSPV., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
45. Targeted Treatment of Inappropriate Sinoatrial Node Tachycardia Based on Electrophysiological and Structural Mechanisms.
- Author
-
de Asmundis C, Pannone L, Lakkireddy D, Beaver TM, Brodt CR, Lee RJ, Sorgente A, Gauthey A, Monaco C, Overeinder I, Bala G, Almorad A, Ströker E, Sieira J, Brugada P, Chierchia GB, La Meir M, and Olshansky B
- Subjects
- Animals, Heart Rate physiology, Humans, Ivabradine therapeutic use, Tachycardia, Tachycardia, Sinus, Arrhythmias, Cardiac, Sinoatrial Node
- Abstract
The purpose of this review is to determine the causal mechanisms and treatment of inappropriate sinoatrial tachycardia (IST), defined as a non-physiological elevation in resting heart rate. IST is defined as a resting daytime sinus rate >100 beats/minute and an average 24-hour heart rate >90 beats/minute. Potential causal mechanisms include sympathetic receptor hypersensitivity, blunted parasympathetic tone, or enhanced intrinsic automaticity within the sinoatrial node (SAN) pacemaker-conduction complex. These anomalies may coexist in the same patient. Recent ex-vivo near-infrared transmural optical imaging of the SAN in human and animal hearts provides important insights into the functional and molecular features of this complex structure. In particular, it reveals the existence of preferential sinoatrial conduction pathways that ensure robust SAN activation with electrical conduction. The mechanism of IST is debated because even high-resolution electroanatomical mapping approaches cannot reveal intramural conduction in the 3-dimensional SAN complex. It may be secondary to enhanced automaticity, intranodal re-entry, or sinoatrial conduction pathway re-entry. Different pharmacological approaches can target these mechanisms. Long-acting β blockers in IST can act on both primarily increased automaticity and dysregulated autonomic system. Ivabradine targets sources of increased SAN automaticity. Conventional or hybrid ablation may target all the described abnormalities. This review provides a state-of-the-art overview of putative IST mechanisms. In conclusion, based on current knowledge, pharmacological and ablation approaches for IST, including the novel hybrid SAN sparing ablation, are discussed., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
46. Brugada Syndrome During Infancy and Childhood: 30 Years' Experience.
- Author
-
Sieira J, Ströker E, Bala G, Overeinder I, Almorad A, La Meir M, Van Dooren S, Brugada P, Chierchia GB, and de Asmundis C
- Subjects
- Child, Humans, Electrocardiography, Brugada Syndrome diagnosis, Brugada Syndrome therapy, Defibrillators, Implantable
- Published
- 2022
- Full Text
- View/download PDF
47. Hybrid-Approach Ablation in Drug-Refractory Arrhythmogenic Right Ventricular Cardiomyopathy.
- Author
-
Monaco C, Galli A, Pannone L, Bisignani A, Miraglia V, Gauthey A, Al Housari M, Mojica J, Del Monte A, Lipartiti F, Rizzi S, Mouram S, Calburean PA, Ramark R, Pappaert G, Eltsov I, Bala G, Sorgente A, Overeinder I, Almorad A, Stroker E, Sieira J, Brugada P, Chierchia GB, La Meir M, and de Asmundis C
- Subjects
- Humans, Recurrence, Treatment Outcome, Arrhythmogenic Right Ventricular Dysplasia surgery, Catheter Ablation methods, Tachycardia, Ventricular etiology, Tachycardia, Ventricular surgery
- Abstract
Management of ventricular arrhythmias (VAs) beyond implantable cardioverter-defibrillator positioning in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) is challenging. Catheter ablation of the ventricular substrate often requires a combination of endocardial and epicardial approaches, with disappointing outcomes due to the progressive nature of the disease. We report the Universitair Ziekenhuis Brussel experience through a case series of 16 patients with drug-refractory ARVC, who have undergone endocardial and/or epicardial catheter ablation of VAs with a thoracoscopic hybrid-approach. After a mean follow-up time of 5.16 years (SD 2.9 years) from the first hybrid-approach ablation, VA recurrence was observed in 5 patients (31.25%): among these, patients 4 patients (80%) received a previous ablation and 1 of 11 patients (9.09%) who had a hybrid ablation as first approach had a VA recurrence (80% vs 9.09%; log-rank p = 0.04). Despite the recurrence rate of arrhythmic events, all patients had a significant reduction in the arrhythmic burden after ablation, with a mean of 4.65 years (SD 2.9 years) of freedom from clinically significant arrhythmias, defined as symptomatic VAs or implantable cardioverter-defibrillator-delivered therapies. In conclusion, our case series confirms that management of VAs in patients with ARVC is difficult because patients do not always respond to antiarrhythmic medications and can require multiple invasive procedures. A multidisciplinary approach involving cardiologists, cardiac surgeons, and cardiac electrophysiologists, together with recent cardiac mapping techniques and ablation tools, might mitigate these difficulties and improve outcomes., Competing Interests: Disclosures Dr. de Asmundis receives research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus and has received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Livanova, Boston Scientific, AtriCure, and Daiichi Sankyo. Dr. Chierchia has received compensation for teaching purposes and proctoring from AF Solutions, Medtronic,Abbott, and Biotronik. Dr. La Meir is a consultant for AtriCure. Dr. Bisignani is consultant for Biotronik. Dr. Miraglia has received an educational grant from the "Foundation Enrico and Enrica Sovena". Dr. Brugada has received compensation for teaching purposes from Medtronic and Biotronik., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
48. Hybrid Ablation of Atrial Fibrillation: A Contemporary Overview.
- Author
-
Marini M, Pannone L, Della Rocca DG, Branzoli S, Bisignani A, Mouram S, Del Monte A, Monaco C, Gauthey A, Eltsov I, Overeinder I, Bala G, Almorad A, Ströker E, Sieira J, Brugada P, La Meir M, Chierchia GB, De Asmundis C, and Guarracini F
- Abstract
Electrical isolation of pulmonary veins (PVI) is the cornerstone of invasive treatment of atrial fibrillation (AF). However, arrhythmia-free survival of a PVI only approach is suboptimal in patients with persistent and long-term persistent AF. Hybrid AF ablation has been developed with the aim of combining the advantages of a thoracoscopic surgical ablation (direct visualization of anatomical structures to be spared and the possibility to perform epicardial lesions) and endocardial ablation (possibility to check line block, confirm PVI, and possibility to perform cavotricuspid isthmus ablation). Patient selection is of utmost importance. In persistent and long-term persistent AF, hybrid AF ablation demonstrated promising results in terms of AF free survival. It has been associated with a relatively low complication rate if performed in centers with expertise in hybrid procedures and experience with both surgical and endocardial ablation. Different techniques have been described, with different approaches and lesion sets. The aim of this review is to provide a state-of-the-art overview of hybrid AF ablation.
- Published
- 2022
- Full Text
- View/download PDF
49. Comparison between the novel diamond temp and the classical 8-mm tip ablation catheters in the setting of typical atrial flutter.
- Author
-
Ramak R, Lipartiti F, Mojica J, Monaco C, Bisignani A, Eltsov I, Sorgente A, Capulzini L, Paparella G, Deruyter B, Iacopino S, Motoc AI, Luchian ML, Osorio TG, Overeinder I, Bala G, Almorad A, Ströker E, Sieira J, Jordaens L, Brugada P, de Asmundis C, and Chierchia GB
- Subjects
- Catheters, Diamond, Humans, Temperature, Treatment Outcome, Tricuspid Valve surgery, Atrial Flutter surgery, Catheter Ablation methods
- Abstract
Purpose: Radiofrequency (RF) catheter ablation is widely accepted as a first-line therapy for cavotricuspid isthmus (CTI)-dependent atrial flutter (AFL). The novel DiamondTemp (DT) catheter with temperature feedback during RF ablation has been released recently on the market. The purpose of this study was to evaluate the impact of DiamondTemp (DT) technology on ablation efficiency during AFL., Methods: In this single-center study, 30 consecutive patients with typical AFL indicated to ablation of CTI were included. The first 15 patients underwent CTI ablation using 8-mm tip catheter, and the following 15 patients underwent temperature-controlled RF ablation using DT catheter. The endpoints were number and mean total duration of RF applications, mean temperature reached in the setting of CTI, procedural times, and fluoroscopy times., Results: There were no significant differences between the two groups concerning baseline characteristics. Mean duration of the each application (71.5 s ± 30.6 vs 12.4 s ± 13.2, p value < 0.001), mean total duration of RF applications (517,73 s ± 377,96 vs 112,8 s ± 43,58; p value < 0.001), procedural times (51.6 min ± 24.2 vs 38.6 ± 8.2; p = 0.03), and fluoroscopy times (16.2 min ± 10.2 vs 8 min ± 4.24; p = 0.005) were longer in the 8-mm ablation catheter group. Mean temperature measurements (51.9 °C ± 3.59 vs 56.7 °C ± 3.34, p value < 0.003) were as well lower in the 8-mm ablation catheter group., Conclusions: Catheter ablation of CTI-dependent AFL by means of DT resulted in a significant reduction of total and single application RF delivery time, procedure, and fluoroscopy times., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
50. Long-Term Outcomes of Pulmonary Vein Isolation in Patients With Brugada Syndrome and Paroxysmal Atrial Fibrillation.
- Author
-
Bisignani A, Conte G, Pannone L, Sieira J, Del Monte A, Lipartiti F, Bala G, Miraglia V, Monaco C, Ströker E, Overeinder I, Almorad A, Gauthey A, Franchetti Pardo L, Raes M, Detriche O, Brugada P, Auricchio A, Chierchia GB, and de Asmundis C
- Subjects
- Humans, Recurrence, Treatment Outcome, Atrial Fibrillation complications, Atrial Fibrillation diagnosis, Atrial Fibrillation surgery, Atrial Flutter, Brugada Syndrome complications, Brugada Syndrome surgery, Catheter Ablation adverse effects, Catheter Ablation methods, Cryosurgery adverse effects, Pulmonary Veins surgery
- Abstract
Background Pharmacological treatment of atrial fibrillation (AF) in the setting of Brugada syndrome (BrS) is challenging. In addition, patients with BrS with an implantable cardioverter-defibrillator (ICD) might experience inappropriate shocks for fast AF. Long-term outcome of pulmonary vein isolation in BrS has not been well established yet, and it is still unclear whether pulmonary vein triggers are the only pathophysiological mechanism of AF in BrS. The aim of the study is to assess the long-term outcomes in patients with BrS undergoing pulmonary vein isolation for paroxysmal AF compared with a matched cohort of patients without BrS. Methods and Results Sixty patients with BrS undergoing pulmonary vein isolation with cryoballoon catheter ablation for paroxysmal AF were matched with 60 patients without BrS, who underwent the same procedure. After a mean follow-up of 58.2±31.7 months, freedom from atrial tachyarrhythmias was achieved in 61.7% in the BrS group and in 78.3% in the non-BrS group (log-rank P =0.047). In particular, freedom from AF was 76.7% in the first group and in 83.3% in the second ( P =0.27), while freedom from atrial tachycardia/atrial flutter was 85% and 95% ( P =0.057). In the BrS group, 29 patients (48.3%) had an ICD and 8 (27.6%) had a previous ICD-inappropriate shock for fast AF. In the BrS cohort, ICD-inappropriate interventions for AF were significantly reduced after ablation (3.4% versus 27.6%; P =0.01). Conclusions Pulmonary vein isolation in patients with BrS was associated with higher rate of arrhythmic recurrence. Despite this, catheter ablation significantly reduced inappropriate ICD interventions in BrS patients and can be considered a therapeutic strategy to prevent inappropriate device therapies.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.